Key Realty School LLC is a real estate and business education organization in Paradise, Nevada. Founded by Ted Federwitz in 1992, the school offers continuing education courses, broker-upgrade courses, and licensing and permit courses. The school is known for serving approximately 50,000 students through a learning system that offers classroom settings, online work, and correspondence work. The school also owns a publishing company, which produces educational materials for the realty sector.
History
Key Realty School was founded in 1992 in Las Vegas.
In 2007, the school's growth prompted expansion into the neighboring California real-estate market. The school now offers a California Real Estate Licensing course, and students across the country can participate in online continuing education or licensing, depending on location.
In 2009, the school earned its BBB accreditation. BBB accreditation is awarded on the basis of 16 factors, including business history, non-existence of complaints, and willingness to resolve customer disputes. Key Realty School has earned an A+ BBB rating.
To date, the school has served more than 50,000 students. About 80 percent of the school's applicants are looking to add more services to what they offer as agents.
Leadership
Key Realty School was founded by Ted Federwitz. Federwitz has brokered over $1 billion worth of real estate sales over the last 20 years and has instructed more than 10,000 real estate students. The school is now owned and operated by multiple partners within the Western United States and is filed as a limited liability company in the State of Nevada.
Courses
Key Realty School offers courses in a variety of topics covering the real estate, brokerage, and business industries. It provides more than 50 approved course curricula and more than 20 approved instructors.
Key Realty provides tutoring in preparation for state or national real estate exams. Tutoring sessions are one-on-one and focus on improving the student's weak points going into the Nevada state-licensing exam.
Key Realty offers online support resources for enrolled students including practice tests and online course work. Students may also qualify for brokerage credits through college education or real-life experience.
Test preparation
Key Realty School offers test prep, crash prep, and seminar sessions for students pursuing certification. One such offering is the PSI Real Estate Exam test-prep session, a one-day class that breaks down the PSI exam and prepares students to pass the exam.
Career enhancement
Key Realty School offers courses in property management as well as resources for pre-test support, training, and counseling. Nevada real estate professionals are required to take 24-hours of property management education and receive a passing score of 75-percent to earn a property management license. Nevada is the only state in the region that requires a property management permit.
Media and reviews
Key Realty School was highlighted in July of 2012 as part of 8 News Now's look at the real estate economy in Las Vegas. The piece focused on local agents and new entrents into the real estate that have studied at Key Realty School. According to 8 News Now, the school has seen an increase in enrolment, pushing class sizes from 20 and 25 people to 40 people or more.
History
Key Realty School was founded in 1992 in Las Vegas.
In 2007, the school's growth prompted expansion into the neighboring California real-estate market. The school now offers a California Real Estate Licensing course, and students across the country can participate in online continuing education or licensing, depending on location.
In 2009, the school earned its BBB accreditation. BBB accreditation is awarded on the basis of 16 factors, including business history, non-existence of complaints, and willingness to resolve customer disputes. Key Realty School has earned an A+ BBB rating.
To date, the school has served more than 50,000 students. About 80 percent of the school's applicants are looking to add more services to what they offer as agents.
Leadership
Key Realty School was founded by Ted Federwitz. Federwitz has brokered over $1 billion worth of real estate sales over the last 20 years and has instructed more than 10,000 real estate students. The school is now owned and operated by multiple partners within the Western United States and is filed as a limited liability company in the State of Nevada.
Courses
Key Realty School offers courses in a variety of topics covering the real estate, brokerage, and business industries. It provides more than 50 approved course curricula and more than 20 approved instructors.
Key Realty provides tutoring in preparation for state or national real estate exams. Tutoring sessions are one-on-one and focus on improving the student's weak points going into the Nevada state-licensing exam.
Key Realty offers online support resources for enrolled students including practice tests and online course work. Students may also qualify for brokerage credits through college education or real-life experience.
Test preparation
Key Realty School offers test prep, crash prep, and seminar sessions for students pursuing certification. One such offering is the PSI Real Estate Exam test-prep session, a one-day class that breaks down the PSI exam and prepares students to pass the exam.
Career enhancement
Key Realty School offers courses in property management as well as resources for pre-test support, training, and counseling. Nevada real estate professionals are required to take 24-hours of property management education and receive a passing score of 75-percent to earn a property management license. Nevada is the only state in the region that requires a property management permit.
Media and reviews
Key Realty School was highlighted in July of 2012 as part of 8 News Now's look at the real estate economy in Las Vegas. The piece focused on local agents and new entrents into the real estate that have studied at Key Realty School. According to 8 News Now, the school has seen an increase in enrolment, pushing class sizes from 20 and 25 people to 40 people or more.
Liana Lee Werner-Gray (born 10 April 1987) is an Australian actress, pageant contestant, and health activist.
Personal life
Werner-Gray was born in Perth, Western Australia but grew up mostly in Alice Springs, Northern Territory. Werner-Gray attended Charles Darwin University in Alice Springs before relocating to New York where she currently resides. In 2009 she took part in Miss Earth Australia 2009, where she received a People's Choice Award and several minor awards for her work with her organization I Love Earth.
Filmography
Movies
Acting roles
*Quarter Lifers, Ellie (2010)
*The Man In The Maze, Megan (2010)
*Backwater, Cass (2011)
*Boomerang (2013)
Production
*Assisting Venus, Production Assistant (2009)
*The Sinatra Club, Production Assistant (2009)
*The Fighter, production assistant (2009)
*Squid Man, First Assistant Director (2010)
Television
* 2004 Yambas Playtime as Princess Liana Imparja Television
* 2006 (the Australian Version)
Personal life
Werner-Gray was born in Perth, Western Australia but grew up mostly in Alice Springs, Northern Territory. Werner-Gray attended Charles Darwin University in Alice Springs before relocating to New York where she currently resides. In 2009 she took part in Miss Earth Australia 2009, where she received a People's Choice Award and several minor awards for her work with her organization I Love Earth.
Filmography
Movies
Acting roles
*Quarter Lifers, Ellie (2010)
*The Man In The Maze, Megan (2010)
*Backwater, Cass (2011)
*Boomerang (2013)
Production
*Assisting Venus, Production Assistant (2009)
*The Sinatra Club, Production Assistant (2009)
*The Fighter, production assistant (2009)
*Squid Man, First Assistant Director (2010)
Television
* 2004 Yambas Playtime as Princess Liana Imparja Television
* 2006 (the Australian Version)
Chrystal Rose was a television presenter.
Life & Career
Rose lived in London until 2005, then Atlanta, Georgia. Chrystal gave birth to her only child when she was 17.
At the age of 18, as a result of being photographed by her local newspaper in Acton, West London, Chrystal began to work as a fashion model and continued in the profession for 10 years. She has also worked as a choreographer, singer, make-up artiste and journalist. In 1984, she won 3rd place in a Channel 4 screenplay writing competition.
Chrystal was a member of the Royal Court Youth Theatre for 3 years, where she acted and sang in many productions. In 1990, she opened and ran her own management and PR company. In 1990, without previous presentation or production skills, inspired by Oprah Winfrey, Chrystal financed her own TV pilots from a bank overdraft facility and by selling personal assets such as her car, television and video. She was successful in creating her own talk show which Carlton TV commissioned and the Chrystal Rose Show ran for four series, although most people have never heard of it. Chrystal also hosted the “Chrystal Style Guide” for two years, which explored the fashion industry.
Chrystal’s first novel, “What a Bitch”, was published in 1996.
In 1997, Chrystal began to run a night club for 30+ professionals called Diamonds. When pitching an idea on in September 2012, she said that Diamonds made £240,000 per year. She also opened her own fashion store in the West End of London called Chrystal’s, where she sold ladies clothes, shoes and accessories, on her own label. She has a line of jackets, tee and sweatshirts on her “What a Bitch” label.
1998 saw the launch of her own record label, Rose Records and she worked with American producer, Alan Glass on her own album, Independent. All 16 tracks are written by Chrystal.
In 1999, Chrystal played lead female in the stage play, Women On Top. She also acted in two Channel 4 programs, “Get Up, Stand Up” and worked with Rory Bremner, playing herself in Bremner, Bird & Fortune.
In 2002, Chrystal played lead Meg in the film, Secrets and penned the novel, NEVER 2 LATE. She has produced three new ideas for TV game shows going into production next year and has interest from 2 companies to develop her idea, Lost 4 Words, into a board game. She co-wrote the sound track for ‘Never 2 Late’ with Paul Atkins, who is the Executive Producer along with Chrystal on the film’s sound track.
In 2012, she was a contestant on , pitching an idea for a word-based television gameshow, but it was not successful.
Life & Career
Rose lived in London until 2005, then Atlanta, Georgia. Chrystal gave birth to her only child when she was 17.
At the age of 18, as a result of being photographed by her local newspaper in Acton, West London, Chrystal began to work as a fashion model and continued in the profession for 10 years. She has also worked as a choreographer, singer, make-up artiste and journalist. In 1984, she won 3rd place in a Channel 4 screenplay writing competition.
Chrystal was a member of the Royal Court Youth Theatre for 3 years, where she acted and sang in many productions. In 1990, she opened and ran her own management and PR company. In 1990, without previous presentation or production skills, inspired by Oprah Winfrey, Chrystal financed her own TV pilots from a bank overdraft facility and by selling personal assets such as her car, television and video. She was successful in creating her own talk show which Carlton TV commissioned and the Chrystal Rose Show ran for four series, although most people have never heard of it. Chrystal also hosted the “Chrystal Style Guide” for two years, which explored the fashion industry.
Chrystal’s first novel, “What a Bitch”, was published in 1996.
In 1997, Chrystal began to run a night club for 30+ professionals called Diamonds. When pitching an idea on in September 2012, she said that Diamonds made £240,000 per year. She also opened her own fashion store in the West End of London called Chrystal’s, where she sold ladies clothes, shoes and accessories, on her own label. She has a line of jackets, tee and sweatshirts on her “What a Bitch” label.
1998 saw the launch of her own record label, Rose Records and she worked with American producer, Alan Glass on her own album, Independent. All 16 tracks are written by Chrystal.
In 1999, Chrystal played lead female in the stage play, Women On Top. She also acted in two Channel 4 programs, “Get Up, Stand Up” and worked with Rory Bremner, playing herself in Bremner, Bird & Fortune.
In 2002, Chrystal played lead Meg in the film, Secrets and penned the novel, NEVER 2 LATE. She has produced three new ideas for TV game shows going into production next year and has interest from 2 companies to develop her idea, Lost 4 Words, into a board game. She co-wrote the sound track for ‘Never 2 Late’ with Paul Atkins, who is the Executive Producer along with Chrystal on the film’s sound track.
In 2012, she was a contestant on , pitching an idea for a word-based television gameshow, but it was not successful.
Introduction
The short-term success rates of transplant surgery have improved remarkably over the past few decades. Early outcomes in transplant recipients are quite good and patients typically return to an active lifestyle after transplantation. With this short-term success, however, the long-term survival of transplanted organs has been rather disappointing and has not progressively improved with the introduction of new immunosuppressive drugs.
To prevent organ rejection in transplant recipients, patients must take potent medication on a daily basis that suppresses the body’s immune system. While this medication reduces the immune response to the donor organ, thereby protecting it, it also suppresses normal immune reactions to challenges by bacteria, viruses and cancer cells, leading to a high risk of developing infections and cancer. In addition, these immunosuppressive drugs often cause undesirable side effects for the patient such as high blood pressure, diabetes, problems with metabolism, kidney damage, and so on. Moreover, immunosuppressive drugs incompletely protect the transplanted organ from rejection, resulting in a chronic loss of organ function. These combined factors have led to serious problems that jeopardize organ and patient survival after around 10 years.
Besides these important health issues for the transplant patient, financial costs are a significant burden for the families and health care systems. It is estimated that the annual cost of immunosuppressive drug therapy exceeds 10,000€/year, and this sum does not include the high costs of managing side-effects.
Taken together, current experiences in organ transplantation indicate a clear need for improving treatment options, especially with the aim of minimising chronic immunosuppressive drug use. The scientific community and national scientific funding agencies are searching for innovative approaches to address this problem.
Project focus
The ONE Study aims to use cell-based therapies to reduce the long-term need for costly and toxic immunosuppressive drugs in renal transplant recipients, by inducing a self-sustaining immune regulation that protects allografts from destruction.
Conditioning the immune response of solid organ transplant recipients towards allograft acceptance using cell-based therapies is now becoming technically feasible and clinically promising. The central focus of this proposed cooperative project is to manufacture distinct populations of regulatory cells, to study the tolerogenic characteristics of these regulatory cell types and to comparatively test their safety and efficacy in minimising pharmacological immunosuppression in solid organ transplantation in a clinical trial of living-donor renal transplant recipients. The health economics of cell therapy as a new medical technology is another essential aspect of The ONE Study work program that will be fully evaluated. True viability of the proposed new cellular treatments will depend not only on their clinical benefit, but also on an acceptable health-economics profile.
Objectives and expected results
1) A first objective of The ONE Study cooperative project is to develop and manufacture distinct populations of immunoregulatory cells for the purpose of cell therapy in transplantation.
Internationally active research groups devoted to cell therapy applications have been assembled to participate in this critical part of the study. Their task is to develop a GMP compliant manufacturing procedure for the immunoregulatory cell population they believe will be useful in organ transplant recipients. At present, regulatory T cell populations, tolerogenic dendritic cells and regulatory macrophages are planned for development into cell products.
2) A second objective, which is the main objective, is to perform a side-by-side comparison of these different cell therapy product treatments in a clinical trial of living-donor renal transplant recipients. This trial will assess the safety of each cell product and provide a first assessment of their comparative potential for reducing long-term immunosuppressive drug therapy.
In addition, knowing the fate of immunoregulatory cells in the recipient after administration is important to understanding their mechanisms of action. As part of The ONE Study project, an innovative approach to tracking of regulatory cells will be pursued by labeling manufactured cell products with combinations of rare earth metals which can be tracked in blood and biopsy material using laser ablation-inductively coupled plasma mass spectrometry.
3) The third objective of The ONE Study is to learn more about the comparative characteristics of suppressive cell types and to assess their tolerogenic capacity and potential for clinical translation.
Groups producing cell therapy products will use the latest technology at experimental workshops to compare the suppressive characteristics of their cell populations. The questions to be answered include whether the cell products share mechanistic activities and whether these activities could potentially be synergistic in a combined cell therapy approach.
Impact
The most important impact of this research project is reducing the need for immunosuppressive drug therapy in organ transplant recipients, thereby significantly improving their survival and quality of life, while at the same time decreasing health care costs. Secondarily, if successful, the results of The ONE Study could be applied to recipients of other organ transplants (liver, heart, etc.) and could add more broadly towards treatment options for immunologically mediated diseases (e.g. multiple sclerosis, inflammatory bowel disorders).
Novelty
The novelty of this proposal is taking a cell therapy approach in humans to reduce the long-term need for pharmacological immunosuppression after organ transplantation. A second area of novelty is the integrative design of this programme, whereby a direct comparison (feasibility, safety, cost and promise of effect) of different cell products is made using a common (ONE) clinical trial protocol design in renal transplant recipients. Thirdly, The ONE Study will lead to the development of important, novel ancillary technologies (GMP-FACS sorting and cell tracking) needed for cell-based therapy in general.
The expected outcome of this comprehensive programme is that the most promising cell therapy products for further clinical trial testing and commercial exploitation will be identified, with the expectation that cell therapy can ultimately reduce the need for immunosuppressive drugs in organ transplant recipients.
The short-term success rates of transplant surgery have improved remarkably over the past few decades. Early outcomes in transplant recipients are quite good and patients typically return to an active lifestyle after transplantation. With this short-term success, however, the long-term survival of transplanted organs has been rather disappointing and has not progressively improved with the introduction of new immunosuppressive drugs.
To prevent organ rejection in transplant recipients, patients must take potent medication on a daily basis that suppresses the body’s immune system. While this medication reduces the immune response to the donor organ, thereby protecting it, it also suppresses normal immune reactions to challenges by bacteria, viruses and cancer cells, leading to a high risk of developing infections and cancer. In addition, these immunosuppressive drugs often cause undesirable side effects for the patient such as high blood pressure, diabetes, problems with metabolism, kidney damage, and so on. Moreover, immunosuppressive drugs incompletely protect the transplanted organ from rejection, resulting in a chronic loss of organ function. These combined factors have led to serious problems that jeopardize organ and patient survival after around 10 years.
Besides these important health issues for the transplant patient, financial costs are a significant burden for the families and health care systems. It is estimated that the annual cost of immunosuppressive drug therapy exceeds 10,000€/year, and this sum does not include the high costs of managing side-effects.
Taken together, current experiences in organ transplantation indicate a clear need for improving treatment options, especially with the aim of minimising chronic immunosuppressive drug use. The scientific community and national scientific funding agencies are searching for innovative approaches to address this problem.
Project focus
The ONE Study aims to use cell-based therapies to reduce the long-term need for costly and toxic immunosuppressive drugs in renal transplant recipients, by inducing a self-sustaining immune regulation that protects allografts from destruction.
Conditioning the immune response of solid organ transplant recipients towards allograft acceptance using cell-based therapies is now becoming technically feasible and clinically promising. The central focus of this proposed cooperative project is to manufacture distinct populations of regulatory cells, to study the tolerogenic characteristics of these regulatory cell types and to comparatively test their safety and efficacy in minimising pharmacological immunosuppression in solid organ transplantation in a clinical trial of living-donor renal transplant recipients. The health economics of cell therapy as a new medical technology is another essential aspect of The ONE Study work program that will be fully evaluated. True viability of the proposed new cellular treatments will depend not only on their clinical benefit, but also on an acceptable health-economics profile.
Objectives and expected results
1) A first objective of The ONE Study cooperative project is to develop and manufacture distinct populations of immunoregulatory cells for the purpose of cell therapy in transplantation.
Internationally active research groups devoted to cell therapy applications have been assembled to participate in this critical part of the study. Their task is to develop a GMP compliant manufacturing procedure for the immunoregulatory cell population they believe will be useful in organ transplant recipients. At present, regulatory T cell populations, tolerogenic dendritic cells and regulatory macrophages are planned for development into cell products.
2) A second objective, which is the main objective, is to perform a side-by-side comparison of these different cell therapy product treatments in a clinical trial of living-donor renal transplant recipients. This trial will assess the safety of each cell product and provide a first assessment of their comparative potential for reducing long-term immunosuppressive drug therapy.
In addition, knowing the fate of immunoregulatory cells in the recipient after administration is important to understanding their mechanisms of action. As part of The ONE Study project, an innovative approach to tracking of regulatory cells will be pursued by labeling manufactured cell products with combinations of rare earth metals which can be tracked in blood and biopsy material using laser ablation-inductively coupled plasma mass spectrometry.
3) The third objective of The ONE Study is to learn more about the comparative characteristics of suppressive cell types and to assess their tolerogenic capacity and potential for clinical translation.
Groups producing cell therapy products will use the latest technology at experimental workshops to compare the suppressive characteristics of their cell populations. The questions to be answered include whether the cell products share mechanistic activities and whether these activities could potentially be synergistic in a combined cell therapy approach.
Impact
The most important impact of this research project is reducing the need for immunosuppressive drug therapy in organ transplant recipients, thereby significantly improving their survival and quality of life, while at the same time decreasing health care costs. Secondarily, if successful, the results of The ONE Study could be applied to recipients of other organ transplants (liver, heart, etc.) and could add more broadly towards treatment options for immunologically mediated diseases (e.g. multiple sclerosis, inflammatory bowel disorders).
Novelty
The novelty of this proposal is taking a cell therapy approach in humans to reduce the long-term need for pharmacological immunosuppression after organ transplantation. A second area of novelty is the integrative design of this programme, whereby a direct comparison (feasibility, safety, cost and promise of effect) of different cell products is made using a common (ONE) clinical trial protocol design in renal transplant recipients. Thirdly, The ONE Study will lead to the development of important, novel ancillary technologies (GMP-FACS sorting and cell tracking) needed for cell-based therapy in general.
The expected outcome of this comprehensive programme is that the most promising cell therapy products for further clinical trial testing and commercial exploitation will be identified, with the expectation that cell therapy can ultimately reduce the need for immunosuppressive drugs in organ transplant recipients.